Impact of thyroid dysfunction on serum cystatin C

被引:276
作者
Fricker, M
Wiesli, P [1 ]
Brändle, M
Schwegler, B
Schmid, C
机构
[1] Univ Zurich Hosp, Dept Internal Med, Div Endocrinol & Diabet, CH-8091 Zurich, Switzerland
[2] Univ Michigan Hlth Syst, Dept Internal Med, Div Endocrinol & Metab, Ann Arbor, MI USA
关键词
serum cystatin C; thyroid dysfunction; creatinine;
D O I
10.1046/j.1523-1755.2003.00925.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Serum cystatin C (CysC) is a novel marker for kidney function that has been claimed to be superior to serum creatinine. Thyroid dysfunction may alter creatinine, which has been found to be increased in hypothyroidism and decreased in hyperthyroidism. This study was performed to evaluate whether changes in CysC and creatinine are parallel during the treatment of hypo- and hyperthyroidism, respectively. Methods. Prospective case series of 22 consecutively referred patients with thyroid dysfunction. Creatinine and CysC were determined at the time of diagnosis of hypo- and hyperthyroidism, and when free thyroxine (fT4) returned into the normal range. Hypothyroid patients were treated with levothyroxine. Hyperthyroid patients were treated with antithyroid drugs, surgery, or radioiodine. Results. Nine patients with hypothyroidism and 13 patients with hyperthyroidism were included. In patients with hypothyroidism mean fT4 (+/-SD) was 4.9 +/- 2.5 pmol/L (reference, 12 to 22) at diagnosis and increased to 16.6 +/- 3.6 pmol/L when patients were treated with levothyroxine. Creatinine decreased from 86 +/- 13 mumol/L (reference, 70 to 105) in the hypothyroid state to 76 +/- 16 mumol/L when fT4 normalized (P = 0.062), whereas CysC increased from 0.84 +/- 0.17 mg/L (reference, 0.63 to 1.33) to 1.1 +/- 0.28 mg/L (P < 0.001). In patients with hyperthyroidism, mean fT4 was 54.6 +/- 22.7 pmol/L (reference, 12 to 22) at diagnosis and decreased to 15.8 +/- 3.6 pmol/L following treatment with antithyroid drugs, thyroid surgery, or radioiodine. Creatinine increased from 67 +/- 15 μmol/L at diagnosis of hyperthyroidism to 75 +/- 9 μmol/L when fT4 normalized (P = 0.004), whereas CysC declined from 1.32 +/- 0.17 mg/L to 0.95 +/- 0.19 mg/L (P < 0.001). Conclusion. Thyroid dysfunction has a major impact on CysC levels. Therefore, thyroid function has to be considered when CysC is used as a marker of kidney function. In contrast to creatinine concentrations, CysC levels are lower in the hypothyroid and higher in the hyperthyroid state as compared with the euthyroid state.
引用
收藏
页码:1944 / 1947
页数:4
相关论文
共 17 条
  • [1] STRUCTURE AND EXPRESSION OF THE HUMAN CYSTATIN-C GENE
    ABRAHAMSON, M
    OLAFSSON, I
    PALSDOTTIR, A
    ULVSBACK, M
    LUNDWALL, A
    JENSSON, O
    GRUBB, A
    [J]. BIOCHEMICAL JOURNAL, 1990, 268 (02) : 287 - 294
  • [2] THE PLACE OF HUMAN GAMMA-TRACE (CYSTATIN-C) AMONGST THE CYSTEINE PROTEINASE-INHIBITORS
    BARRETT, AJ
    DAVIES, ME
    GRUBB, A
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1984, 120 (02) : 631 - 636
  • [3] Bökenkamp A, 1999, CLIN CHEM, V45, P1866
  • [4] RENAL-FUNCTION AND ELECTROLYTE LEVELS IN HYPERTHYROIDISM - URINARY PROTEIN EXCRETION AND THE PLASMA-CONCENTRATIONS OF UREA, CREATININE, URIC-ACID, HYDROGEN-ION AND ELECTROLYTES
    FORD, HC
    LIM, WC
    CHISNALL, WN
    PEARCE, JM
    [J]. CLINICAL ENDOCRINOLOGY, 1989, 30 (03) : 293 - 301
  • [5] Determination of serum cystatin C: Biological variation and reference values
    Galteau, MM
    Guyon, M
    Gueguen, R
    Siest, G
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2001, 39 (09) : 850 - 857
  • [6] Keevil BG, 1998, CLIN CHEM, V44, P1535
  • [7] Kos J, 1997, CLIN CANCER RES, V3, P1815
  • [8] Consistent reversible elevations of serum creatinine levels in severe hypothyroidism
    Kreisman, SH
    Hennessey, JV
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (01) : 79 - 82
  • [9] INCREASED SERUM CREATININE IN THE ABSENCE OF RENAL-FAILURE IN PROFOUND HYPOTHYROIDISM
    LAFAYETTE, RA
    COSTA, ME
    KING, AJ
    [J]. AMERICAN JOURNAL OF MEDICINE, 1994, 96 (03) : 298 - 299
  • [10] Laterza OF, 2002, CLIN CHEM, V48, P699